Catabasis lands $39M Series A for diabetes programs

Just days after raising its first tranche, Cambridge, MA-based Catabasis Pharmaceuticals announced this morning that it has completed a $39.6 million Series A venture round. The round, large for a Series A, was led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures with Advanced Technology Ventures participating. Catabasis was launched in 2008 by a pair of veterans from Sirtris Pharmaceuticals after that developer was snapped up by GlaxoSmithKline. And like Sirtris,...